mezigdomide
mezigdomide: 6 clinical trials tracked.
mezigdomide evidence translation
What we can confirm
6 tracked trials
What it means
What to watch
Prepared research question
What is verified about mezigdomide, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 3 study sponsors
Related indications
Clinical Trial Registry Records (6)
A Phase 1 Study of Menin-KMT2A Inhibitor Ziftomenib (KO-539) in Combination With Cereblon E3 Ligase Modulator Mezigdomide (CC-92480) in Adolescents and Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Primary endpoint: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Teclistamab and Mezigdomide for Relapsed/Refractory Multiple Myeloma
Primary endpoint: Number of Participants With Dose Limiting Toxicity Assessed by CTCAE v5.0
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of T Cell Engaging Bi/Tri-specific Antibodies in Subjects With MM
Primary endpoint: Number of Participants with Adverse Events (AE)s
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Primary endpoint: Incidence of adverse events (AEs)
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2
Primary endpoint: Progression-free Survival (PFS)
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
Primary endpoint: Phase 1 (Dose-escalation): Maximum Tolerated Dose (MTD)